BOCA RATON, Fla., June 29 /PRNewswire-FirstCall/ -- Nabi
Biopharmaceuticals (Nasdaq: NABI) announced today that its chairman, chief
executive officer and president, Thomas H. McLain, has been appointed to the
Board of Directors of the Biotechnology Industry Organization (BIO), effective
June 21, 2005. Mr. McLain is one of eleven new Board members, who will each
serve two-year terms.
BIO represents more than 1,000 biotechnology companies, academic
institutions, state biotechnology centers and related organizations in all 50
U.S. states and 33 other nations. BIO members are involved in the research and
development of healthcare, agricultural, industrial and environmental
biotechnology products.
"Biotechnology's impact on human health has never been greater; its
discoveries are beginning to realize their great promise. I am honored to
accept this Board position, as our industry continues to serve as a leading
force in the advancement of 21st century medicine," said Mr. McLain.
Mr. McLain joined Nabi Biopharmaceuticals in 1998 and today serves as
chairman, chief executive officer and president of the company. From 1988 to
1998, Mr. McLain was employed by Bausch & Lomb, Incorporated. He earned his
B.A. in Economics at College of the Holy Cross and an M.B.A. from the William
E. Simon Graduate School of Business at the University of Rochester. He is a
member of the Board of Directors of Eastman Chemical Company and serves as the
Chairman of BioFlorida.
"Tom McLain is a widely recognized leader in the emerging life sciences
arena both nationally and internationally," said Florida Governor Jeb Bush.
"As Florida is increasingly positioned at the epicenter of this industry, we
are fortunate to have someone of Tom's caliber contributing on a national
scale. I applaud BIO's decision to recognize Tom's commitment to and noted
achievements in biotechnology, and look forward to his ongoing leadership to
escort the industry to new heights."
"Tom McLain's knowledge, experience and vision make him an ideal addition
to our Board of Directors," said BIO President James Greenwood. "In
particular, we value his expertise in vaccines and his role in the emergence
of biotech in Florida."
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering
the immune system to develop and market products that fight serious medical
conditions. We are poised to capture large, commercial opportunities in our
four core business areas: Gram-positive bacterial infections, hepatitis,
kidney disease (nephrology), and nicotine addiction. We have three products on
the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune
Globulin (Human)], and Aloprim(TM) [Allopurinol sodium (for injection)] and a
number of products in various stages of clinical and preclinical development.
The company filed its Marketing Authorization Application in Europe for its
product candidate, StaphVAX(R) [Staphylococcus aureus Polysaccharide Conjugate
Vaccine], in December 2004. The application was accepted for review in
January 2005. StaphVAX is currently in a confirmatory Phase III clinical
trial in the U.S. StaphVAX is designed to prevent the most dangerous and
prevalent strains of Staphylococcus aureus bacterial infections. S. aureus
bacteria are a major cause of hospital-acquired infections and are becoming
increasingly resistant to antibiotics. The company's other products in
development include Altastaph(TM) [Staphylococcus aureus Immune Globulin
Intravenous (Human)], an antibody for prevention and treatment of S. aureus
infections, NicVAX(TM) [Nicotine Conjugate Vaccine], a vaccine to treat
nicotine addiction, and Civacir(TM) [Hepatitis C Immune Globulin (Human)], an
antibody for preventing hepatitis C virus re-infection in liver transplant
patients. For additional information on Nabi Biopharmaceuticals, please visit
our website at: http://www.nabi.com .
This press release contains forward-looking statements that reflect the
company's current expectations regarding future events. Any such forward-
looking statements are not guarantees of future performance and involve
significant risks and uncertainties. Actual results may differ significantly
from those in the forward-looking statements as a result of any number of
factors, including, but not limited to, risks relating to the possibility that
our confirmatory Phase III clinical trial for StaphVAX or our plans to
commercialize StaphVAX in the European Union and United States may not be
successful; the possibility that we may not realize the value of our
acquisition of PhosLo; the company's ability to raise additional capital on
acceptable terms; the company's dependence upon third parties to manufacture
its products; the company's ability to utilize the full capacity of its
manufacturing facility; the impact on sales of Nabi-HB from patient treatment
protocols and the number of liver transplants performed in HBV-positive
patients; reliance on a small number of customers; the future sales growth
prospects for the company's biopharmaceutical products; and the company's
ability to obtain regulatory approval for its products in the United States or
abroad or to successfully develop, manufacture and market its products. These
factors are more fully discussed in the company's Annual Report on Form 10-K
for the fiscal year ended December 25, 2004 filed with the Securities and
Exchange Commission.
SOURCE Nabi Biopharmaceuticals
 back to top
Related links:
http://www.nabi.com
CONTACT:
Constance C. Bienfait, Vice President,
Investor Relations of Nabi Biopharmaceuticals, +1-561-989-5800
|
